Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Off-label dupilumab safe, effective for atopic dermatitis in kids

13 Feb 2020

Off-label dupilumab shows potential in the treatment of atopic dermatitis (AD) in children, although appropriate dosing recommendations have yet to be established, suggests a new study.

Researchers performed a multicentre retrospective review including 124 paediatric AD patients (mean age at initiation, 13.0±3.9 years; 32.3 percent female) with moderate-to-severe disease. Qualitative interpretation for symptom improvement, as judged by the physician and documented in the medical record, was translated into a 5-point score and set as the primary outcome.

After a 9-week delay, 89.5 percent (n=111) of the participants were able to initiate dupilumab treatment. The remaining patients (n=13) failed to receive treatment based on their payer denial to cover the cost. The mean loading dose was 8.7±2.2 mg/kg.

At baseline, majority (70.5 percent) of the patients had severe disease, while 29.5 percent had moderate AD. Over a mean follow-up duration of 9 months, the children received an average of 16.4 doses. At the end of the study, majority (64.3 percent) of the patients showed improvements in investigator global assessment scores of at least 2 points.

In comparison, 22.1 percent of children showed a 1-point improvement while 12.6 percent experienced no change in symptoms. Most of the participants believed their eczema had eased and wanted to continue taking dupilumab.

Adverse events occurred rarely. The most common of which was worsening conjunctivitis, detected in 10 patients. There were two cases of viral upper respiratory infection, three injection site reactions and six facial eruptions. One patient discontinued treatment due to lack of response at 6 months.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.